New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders ( Data to be Presented April 15th at EASL...)

HOME >> MEDICINE >> TECHNOLOGY

New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders

Data to be Presented April 15th at EASL Conference in Barcelona, Spain

VANCOUVER and SAN DIEGO, CA, April 11, 2007 /PRNewswire-FirstCall/ - MIGENIX Inc. , a clinical-stage developer of drugs for infectious diseases, has received new top-line results confirming the previously announced clinical results (November 6, 2006) indicating evidence of clinical benefit, safety and tolerability in a Phase II study using the oral alpha-glucosidase inhibitor, celgosivir (MX-3253), in combination with pegylated interferon and ribavirin.

In addition to confirming the overall conclusions of the original study analysis, retesting resulted in a larger percentage of patients achieving an Early Virologic Response(x) ("EVR") rate with celgosivir plus peginterferon alfa-2b and ribavirin (the "triple combination") as compared to treatment with peginterferon alfa-2b and ribavirin alone (the "control treatment") in patients with chronic hepatitis C virus genotype 1 infections who were characterized as non-responders to prior therapy with optimized pegylated interferon plus ribavirin, achieving:

    -   42% (5/12) EVR with the celgosivir triple combination arm compared to

        10% (1/10) EVR in the control treatment arm. This compares with 33%

        (4/12) EVR (triple combination) vs 10% (1/10) (control treatment) in

        the original study results. (x) EVR = 2 log(10) or greater

        HCV viral load reduction at 12 weeks.


    -   1.63 log(10) (triple combination) mean HCV viral load reduction

        ("VLR") compared to a 0.92 log(10) VLR (control treatment). This

        compares with a 1.2 log(10) VLR (triple combination) vs a 0.4 log(10)

        VLR (control treatment) in the original study results.


    -   a more rapid onset of treatment effect as measured by VLR within the

        first 2 weeks of therapy in the triple combination as compared to the

        control treatment.

Thes
'"/>

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference

Post Your Comments:

( Data to be Presented April 15th at EASL...)New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders,Health